Atlas Trials

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT04910568 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04910568
Sponsor
Genentech, Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2021-07-26
Primary completion
2028-12-21
Enrollment
186

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.